• FAISL lncRNA Prevents FAK Proteolysis to Drive TNBC Metastas

  2026-07-06

  The reference study identifies the long noncoding RNA FAISL as a direct stabilizer of focal adhesion kinase (FAK) in triple negative breast cancer (TNBC), blocking Calpain 2-mediated proteolysis and promoting tumor progression. These findings illuminate a previously unrecognized mechanism of FAK regulation in cancer and suggest new therapeutic targets for aggressive breast tumors.

• HATU in Peptide Synthesis: Mechanism, Evidence & Workflow In

  2026-07-06

  HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) is a highly efficient amide bond formation reagent. Its use in peptide synthesis delivers rapid, high-yield coupling with precise carboxylic acid activation. APExBIO's HATU (SKU A7022) is validated for reliable, reproducible results in advanced research workflows.

• Applied Workflows with EZ Cap™ Human PTEN mRNA (ψUTP) Delive

  2026-07-05

  EZ Cap™ Human PTEN mRNA (ψUTP) empowers robust PTEN restoration and immune-evasive gene expression in translational cancer research. Its Cap 1 structure and pseudouridine modifications uniquely support advanced, stable mRNA delivery for resistance-reversal oncology workflows.

• Synergistic Inhibition of Melanogenesis by GRE: Mechanisms a

  2026-07-04

  This study demonstrates that a combination of glabridin, resveratrol, and ellagic acid (GRE) potently inhibits melanin production, tyrosinase activity, and associated pro-melanogenic signaling in vitro. By targeting MITF and CREB pathways, GRE provides a mechanistic rationale for its application in pigmentation regulation and anti-inflammatory research.

• Salinomycin: Polyether Ionophore Antibiotic for HCC Research

  2026-07-03

  Salinomycin, a polyether ionophore antibiotic from APExBIO, is redefining hepatocellular carcinoma workflows by targeting the Wnt/β-catenin pathway and inducing apoptosis with high specificity. This guide translates evidence-backed protocols and troubleshooting strategies into actionable insights for robust cancer research.

• Z-DEVD-FMK: Advancing Caspase-3 Inhibition for Translational

  2026-07-03

  Z-DEVD-FMK, a benchmark caspase-3 inhibitor from APExBIO, is redefining translational research in apoptosis and neuroprotection. By integrating mechanistic insight—such as cross-talk between caspase and calpain pathways—with strategic workflow guidance, this article bridges foundational cell death biology with actionable experimental design. We contextualize Z-DEVD-FMK’s dual inhibition in the emerging landscape of viral immunoevasion, spotlighting its role in SADS-CoV infection models, and provide protocol and experimental optimization tips for translational researchers.

• Nutlin-3a: Potent MDM2 Inhibitor for p53 Pathway Activation

  2026-07-02

  Nutlin-3a is a highly specific small-molecule MDM2 inhibitor that stabilizes and activates p53, resulting in controlled cell cycle arrest and apoptosis induction in cancer cells. It demonstrates sub-micromolar potency and robust experimental utility in oncology research. This dossier summarizes its mechanism, experimental benchmarks, and best practices.

• ECL Chemiluminescent Substrate Detection Kit: Transforming Q

  2026-07-02

  Explore the unique capabilities of the ECL Chemiluminescent Substrate Detection Kit (Enhanced) for advanced protein immunodetection. This article reveals how its high sensitivity and prolonged luminescence enable robust, quantitative insights in metabolic and translational research.

• NET Formation in CML: PAD4 Dependency and Tyrosine Kinase In

  2026-07-01

  This study reveals that neutrophil extracellular trap (NET) formation is significantly elevated in chronic myeloid leukemia (CML) and is further modulated by tyrosine kinase inhibitors (TKIs), particularly ponatinib. The research highlights PAD4-driven histone citrullination as a mechanistic driver of NET production, suggesting new therapeutic and risk-assessment considerations for CML and TKI-associated vascular complications.

• CARD8 Inflammasome Activation Induces Pyroptosis in Human T

  2026-07-01

  The referenced study reveals that inhibition of dipeptidyl peptidases, particularly with Val-boroPro (Talabostat mesylate), activates the CARD8 inflammasome and triggers pyroptosis in primary human T cells. These findings expand the known landscape of inflammasome signaling and suggest new mechanistic routes for modulating T cell fate in immunology and cancer research.

• Ouabain as a Selective Na⁺/K⁺-ATPase Inhibitor: Bridging Ion

  2026-06-30

  Explore the scientific foundation and innovative applications of Ouabain, a selective Na⁺/K⁺-ATPase inhibitor, in advanced ion transport and senescence research. This article delivers unique insights into integrating recent senolytic discoveries with practical assay design, setting it apart from existing reviews.

• Miltefosine in Hematology: Beyond PI3K/Akt Inhibition

  2026-06-30

  Explore how Miltefosine, a PI3K/Akt pathway inhibitor, revolutionizes hematology by promoting neutrophil differentiation and restoring immune balance. This article uniquely analyzes the molecular interplay and translational impact of Miltefosine, distinguishing it from protocol-focused guides.

• Mubritinib Enhances Cisplatin Efficacy in NSCLC via Mitochon

  2026-06-29

  The referenced study demonstrates that Mubritinib (TAK 165), a mitochondrial complex I inhibitor, significantly enhances cisplatin's antitumor effects against non-small cell lung cancer (NSCLC) by increasing oxidative stress and apoptosis. This work highlights the potential of targeting mitochondrial function to overcome cisplatin resistance and provides a mechanistic basis for combination therapies in lung cancer.

• Naloxone Hydrochloride: Optimizing Opioid Receptor Antagonis

  2026-06-29

  Naloxone hydrochloride enables reproducible, high-impact opioid receptor antagonist workflows—spanning neural stem cell, immune modulation, and behavioral studies. This article delivers actionable protocols, troubleshooting strategies, and evidence-based insights to maximize experimental rigor with APExBIO’s high-purity compound.

• Rapakinin-Induced Vasorelaxation: Mechanisms in Hypertensive

  2026-06-28

  This study uncovers that rapakinin, a rapeseed-derived peptide, induces vasorelaxation in hypertensive rat mesenteric arteries via a prostaglandin I2 (PGI2)-IP receptor pathway, followed by activation of the CCK1 receptor. These findings highlight a distinct, nitric oxide-independent mechanism for blood pressure modulation, expanding the therapeutic landscape for vascular dysfunction.

15574 records 1/1039 page Next 12345 下5页 Last page